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Abstract
Background: Anti-tuberculosis drug resistance is an emerging health problem in Kenya and especially in slums.
Slum environments create a conducive environment for the spread of tuberculosis (TB) due to high population
density and lack of basic amenities such as decent housing, access to clean water, lack of drainage and basic
sanitation. Furthermore, ineffective health services in crowded and poorer populations, poor patient compliance, a
large pool of untreated cases, delayed diagnosis and inappropriate treatment regimens are likely to favour selection
and spread of drug resistant Mycobacterium tuberculosis (Mtb) strains in such settings, however, precise data
on this problem are only sparsely available. To address this question, this study aimed at determining drug
resistance patterns of Mtb strains obtained from pulmonary TB patients who sought health care in randomly
selected informal settings.
Methods: This is a cross-sectional study conducted between September 2014 and March 2015, sputum
samples were collected from 223 consenting adult patients and subjected to primary isolation and drug
susceptibility testing. Socio-demographic data was collected and all data analysed using SPSS v20.
Results: Drug susceptibility testing against first line drugs was successfully carried out on 184 isolates.
Resistance to at-least one drug was observed in 33 % of the isolates. The highest prevalence of resistance to
any drug was identified against isoniazid,(INH) (23.9 %) followed by Ethambutol (EMB) (13.6 %). The highest
proportion of mono resistance was observed against INH, 25 (13.6 %). Multidrug resistance (MDR) was
observed in 4.4 % of the new cases. There was no significant difference in the proportion of any resistance
by sex, age or previous treatment.
Conclusion: Levels of drug resistance have reached an alarming level in this population. Capacity of
laboratories to conduct TB culture and DST should be strengthened in order to adequately manage TB
patients and stop further creation and spread of MDR TB.
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Background
Tuberculosis (TB) is an infectious disease that causes
morbidity and mortality in the world, especially in poor
resource settings and is often the first indicator of HIV
infection [1, 2]. According to the world health organisa-
tion (WHO), there were an estimated 9.0 million inci-
dence cases of TB globally [3]. More than half of these
cases (56 %) were in the South-East Asia and Western
Pacific Regions, while 29 % were in the African Region
[3]. Global surveillance has shown that drug resistance
towards TB threatens the progress made by TB control
programs [4]. Inappropriate use of antibiotics in treat-
ment of drug susceptible patients, sub-optimal treatment
regimes and failure to complete treatment treatment in
drug susceptible patients leads to drug resistance.
Multidrug-resistant TB (MDR-TB), caused by Mycobac-
terium tuberculosis complex strains (MTBC) that are
resistant to at least isoniazid and rifampicin, has become
a menace in many parts of the world [5–7]. This has
therefore resulted in high treatment failures and death
rates due to the complexities in diagnosis and treatment
[8, 9]. In 2013, WHO estimated that 480,000 people
developed MDR-TB globally. Recent surveys have re-
ported the emergence of untreatable form of TB, exten-
sively drug resistant TB (XDR TB). These strains are
resistant to isoniazid and rifampicin, in addition to any
fluoroquinolone and at least one of three injectable
drugs (amikacin, kanamycin, or capreomycin) [10, 11].
Kenya has a high TB burden and is ranked among the
22 high burden TB countries in the world, and has the
fifth highest burden in Africa [3]. According to WHO,
the MDR-TB prevalence in Kenya was 2.6 % in new
cases and 13 % in retreatment cases [3]. TB is common
in slums and resistant strains are also becoming more
frequent in this population [12]. Especially, high popula-
tion density, poor sanitation, poorly built housing with
low lighting and air movement are likely to create a
conducive environment for the spread of this pathogen
in these slums. TB patients infected with drug resistant
strains can easily infect upto 15 other individuals [12].
Nairobi houses more than 102 slums scattered in the
expanse of the city [13]; more than half of the popula-
tion now lives in slums which, however, cover just 5 %
of the city land area [14]. Lack of employment oppor-
tunities in rural areas makes people to migrate to urban
areas in search of job opportunities. Low income levels
among many city migrants forces them to live in slum
areas and hence complicates the situation further in
these poor urban areas. In these informal settlements,
people live in extreme poverty with most people making
less than one US dollar a day [15].
Once introduced, drug resistant TB is likely to be
spread in urban slums fostered by poor health services
in overcrowded and poorer populations who do not stick
to their prescriptions in combination with soaring rates
of HIV. In addition, inconsistent, incorrect treatments
being taken, delayed diagnosis or even unreliable drug
supply contributes to drug resistance [16]. When TB
control programs fail to adequately treat drug resistant
forms of TB, then further resistance is acquired leading
to the circulation of highly resistant of M. tuberculosis
strains. The effects of generation of high-grade drug re-
sistance due to incomplete treatment is not only grave
for the patient, but for the community at large, since the
transmission mechanism of drug resistant strains is simi-
lar to that of susceptible [17].
In turn, precise information on drug susceptibility
patterns of circulating MTBC strains is an important
factor of TB control and surveillance. Accurate and
prompt detection of MDR strains is key to proper
management of cases and is an indicator of the quality
of TB control in the country. However, especially in
slum setting, precise data on drug susceptibility patterns
is only sparsely available.
To address this gap, this study aimed to establish the
prevalence of drug resistance strains in selected urban
slums of Nairobi and determine factors that may be
important in driving the rise in cases. A cross sectional
study was conducted in seven randomly selected health
centres located in urban slums in Nairobi from September
2014 to May 2015. Samples obtained were subjected to
primary isolation and drug susceptibility testing to the first
line drugs.
Methods
Study setting and population
This cross sectional study was conducted in seven
randomly selected health centres located in urban slums
in Nairobi (Fig. 1) from September 2014 to May 2015.
Majority of the patients seeking health care in these
centres were from the slums. A significant proportion of
the population in the slums lives below the poverty line
and they try to sustain themselves through various
means, including informal sector activities such as petty
trade or casual labour Additional file 1.
Smear-positive cases of TB patients aged ≥18 years
who consented to the study and living in slums were
enrolled into the study. They completed a questionnaire
containing demographic information, history of anti-TB
treatment, history of contact with TB cases, alcohol
usage and smoking history.
Sputum collection and processing
Good quality spot and early morning sputum samples
were collected in sterile 50 ml conical tubes (Corning®,
MA, U.S.A) and then transported to the BSL 3 laboratory
based in KEMRI in temperature controlled cool boxes.
The samples were processed by the standard N-acetyl- L-
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cysteine (NALC)-NaOH method and concentrated at
3000 × g for 15 min. The sediment was reconstituted to
2.5 ml with phosphate buffer (pH 6.8) to make suspen-
sions for the smears and cultures.
Culture and identification
The sputum samples were cultured for the presence
of M. tuberculosis on BACTEC MGIT 960 system
(Becton Dickinson Microbiology systems, Sparks, MD,
USA) according to the manufacturers’ recommenda-
tions [18]. The MGIT tubes (7 ml) were inoculated
with the processed specimen and incubated at 37 °C
in the BACTEC MGIT 960 machine. They were mon-
itored automatically every 60 min for increase in
fluorescence. The cultures were tested until positive
for a maximum of 6 weeks. The isolates from MGIT
960 tubes were confirmed to be M. tuberculosis by
microscopic observation for serpentine cord formation
and inoculation onto blood agar plate to rule out
contamination.
Drug susceptibility testing
All M. tuberculosis strains were subjected to drug sus-
ceptibility testing (DST) to first line anti-tuberculosis
drugs with an exception of PZA. DST using MGIT 960
was done following standard procedures according to
the manufacturer’s recommendation [18]. Final drug
concentrations were 1.0 μg/ml for Streptomycin (STR),
0.1 μg/ml for Isoniazid (INH), 1.0 μg/ml for Rifampicin
(RIF) and 5.0 μg/ml for Ethambutol (EMB). The
results were automatically interpreted by the BAC-
TEC MGIT 960 instrument and reported as either
susceptible or resistant.
Quality control
The reference strain M. tuberculosis H37Rv (ATCC27294),
which is susceptible to all standard anti-tuberculosis
drugs, was used as susceptible control. All bacterial sus-
pensions used for DST in MGIT 960 were checked for
purity by culture on blood agar.
Statistical analysis
Data was entered and analyzed by SPSS version 20.0
statistical software (SPSS Inc. Chicago). Descriptive
analysis was done to depict the socio-demographic
variables and proportions of drug resistant TB. Odds
ratios (OR) and 95 % confidence intervals (95 % CI)
were calculated to examine the association of risk
factors and resistance. Bivariate analysis was used to
evaluate the independent association between drug
resistance and previous TB infection, previous TB
treatment and contact with TB cases. Associations
with p-values less than or equal to 0.05 were consid-
ered statistically significant.
Fig. 1 Map showing slums in Nairobi. Source: Source: http://sdinet.org/wp-content/uploads/2015/04/Nairobi_slum_inventory_jan_09.pdf.
Nairobi province: distribution of infomal settlements
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Results
A total of 223 sputum samples were collected from
smear positive pulmonary tuberculosis (PTB) patients.
Of these, 39 (17.5 %) were either culture negative or
contaminated and thus excluded from further analysis.
Among the 184 (82.5 %) included in this study, 160
(87 %) were new cases while 24 (13 %) were retreatment
cases (Table 1). One hundred and twenty seven (69 %)
were males, 110 (59.8 %) were married and 87 (47.3 %)
had completed secondary school education with 39.7
and 12.5 % having acquired primary level and tertiary
education respectively. A majority of the participants
(75 %) were casual workers with 62 % of them living
with less than five members in their households. Eight-
een percent of them had a smoking history while 38
(20.7 %) consumed alcohol. The mean age of the pa-
tients was 32.09 (SD ± 7.69) ranging from 18 to 53 years.
Table 1 describes the socio-demographic characteristics
of the study population.
DST was performed for all the 184 Mycobacterium
tuberculosis isolates for the first line anti-TB drugs
(INH, RIF, STR, and EMB) except for PZA. Prevalence
of any resistance to at least one drug was 61 (33 %, 95 %
CI 26.21–39.79). Any resistance to INH, STR, RIF and
EMB was 44 (23.9 %), 13 (7.1 %), 12 (6.5 %) and 25
(13.6 %) respectively. The highest proportion of mono
resistance was observed against INH, 25 (13.6 %),
followed by EMB 11 (6 %), STR 4 (2.2 %) and RIF 1
(0.5 %). MDR was observed in 2 (8 %) of the retreatment
cases and 7 (4.4 %) of the new cases. Only four (2.2 %)
of all the isolates were resistant to all the drugs tested as
shown in Table 2.
Bivariate analysis showed that there was no significant
association of MDR with previous TB infection (p = 0.622,
95 % CI), previous treatment (p = 0.332, 95 % CI) or
contact with TB cases (p = 0.693, 95 % CI) (Table 3).
Discussion
Information on drug sensitivity patterns MTBC isolates
against anti-TB agents is a crucial aspect in tuberculosis
control and surveillance. Tuberculosis treatment for fully
susceptible patients starts with a 4-drug regimen: isonia-
zid, rifampicin, pyrazinamide, and either ethambutol or
streptomycin. After 2 months of therapy, pyrazinamide
is stopped and the patient continues with isoniazid and
rifampicin daily for 4 more months. Analysis of rates of
resistance is helpful in understanding MDR TB trends
and provides an indicator of the quality of TB control in
the country. Furthermore, they help to identify hot spots
of MDR TB e.g. in slum settings, thus, allowing targeted
action to control further spread of MDR TB. Indeed,
prompt and accurate drug resistance detection is im-
portant in the selection of the appropriate regimen to
which the strain is susceptible to and in timely initiation
of treatment. Early diagnosis also facilitates appropriate
measures to prevent transmission.
In this study, resistance to one or more first line anti-
TB drugs was 33 %. Compared to previous data, this is
higher as reports from other studies conducted in
Nairobi which found rates of 18.8 and 18.1 % [19, 20]
and might indicate increasing resistance rates in the
region. This is supported by a recent study by Ndungu
et al. from a survey conducted in Nairobi who also re-
ported resistance levels of around 30 % [21]. The differ-
ences in the drug resistance rates among the study areas
could be due to sampling, inadequate diagnosis and
treatment and poor patient compliance to treatment.
The findings of this study show the highest rate of mono
resistance to be associated with INH (13.6 %). Previous
studies conducted in Nairobi reported that the proportion
of resistance to INH was within the range of 6.5–12.9 %
[19–21]. Studies conducted in Ethiopia, Uganda and
Zambia reported lower resistance rates of 9.5, 2.5 and
Table 1 Socio-demographic characteristics of participants
Characteristic Male (n = 127) Female (n = 57) Total (N = 184)
Age
18–23 9 (7.1 %) 12 (21.1 %) 21 (11.4 %)
24–29 39 (30.7 %) 17 (29.8 %) 56 (30.4 %)
30–35 32 (25.2 %) 17 (29.8 %) 49 (26.6 %)
36–41 30 (23.6 %) 9 (15.8 %) 39 (21.2 %)
42–47 11 (8.7 %) 2 (3.5 %) 13 (7.1 %
48+ 6 (4.7 %) 0 (0.0 %) 6 (3.3 %)
Marital status
Married 81 (63.8 %) 29 (50.9 %) 110 (59.8 %)
Single 44 (34.6 %) 26 (45.6 %) 70 (38.0 %)
Divorced 2 (1.6 %) 2 (3.5 %) 4 (2.2 %)
Education
Never 0 (0.0 %) 1 (1.8 %) 1 (0.5 %)
Primary 48 (37.8 %) 25 (43.9 %) 73 (39.7 %)
Secondary 59 (46.5 %) 28 (49.1 %) 87 (47.3 %)
College 20 (15.7 %) 3 (5.3 %) 23 (12.5 %)
House type
Homeless 2 (1.6 %) 0 (0.0 %) 2 (1.1 %)
Hut 17 (13.4 %) 11 (19.3 %) 28 (15.2 %)
Iron sheet 39 (30.7 %) 18 (31.6 %) 57 (31.0 %)
Stonewall 69 (54.3 %) 28 (49.1 %) 97 (52.7 %)
Source of Income
Unemployed 9 (7.1 %) 5 (8.8 %) 14 (7.6 %)
Casual worker 97 (76.4 %) 41 (71.9 %) 138 (75.0 %)
Salaried 18 (14.2 %) 2 (3.5 %) 20 (10.9 %)
Dependant 3 (2.4 %) 9 (15.8 %) 12 (6.5 %)
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4.5 % respectively [22–24]. A higher INH resistance rate
of 14.9 % was observed in Mozambique [25]. High INH
rates could be associated with unfavourable treatment
outcomes and its wide and longer use in treatment of TB.
In our study STR mono-resistance was 2.2 %. This rate
is lower than similar studies conducted in Nairobi which
reported rates of 5.1 and 5.2 % respectively [19, 21].
Higher STR rates of 14.8 and 26 % were reported in
Benin and Ethiopia respectively [22, 26]. RIF mono-
resistance was observed in only one isolate (0.5 %).
Similar low resistance rates were reported in Nairobi
and Uganda [20, 23]. The detected rate was however
lower compared to other studies reported in Nairobi [19,
21, 22]. EMB monoresistance was 6 % in this study. Dif-
ferent resistance rates towards EMB have been reported
in Nairobi, ranging from 2.6 to 8 % [19–21]. However,
lower EMB rates of 0.3 and 0.9 % have been described in
Ethiopia and Uganda respectively [22, 23].
The prevalence of MDR TB in this study was 4.9 %.
Among new cases, the MDR TB rate was observed to
be 4.4 and 8.3 % among retreatment cases. This
proportion was however higher than the 4.3, 3.4 and
2.3 % reported in previous studies conducted in
Nairobi on different populations [19–21]. Studies con-
ducted in Ethiopia and Uganda and showed lower
MDR TB rates of 1.4 and 2.3 % respectively [22, 23].
The findings of this study are however lower com-
pared to the 7.7 % reported in Swaziland, 5.8 % in
Mozambique and 5.2 % in Somalia [27–29]. Egypt
also had a high MDR TB rate of 13.8 % [30]. This
Table 2 Drug resistance patterns of Mycobacterium tuberculosis isolates
Category New cases Retreatment cases All cases
N (%) 95 % CI N (%) 95 % CI N (%) 95 % CI
Total patients N = 160 N = 24 N = 184
Any Resistance 56 (35 %) 27.61–42.39 5 (20.8) 4.56–37.04 61 (33.1) 26.3–39.3
Any Resistance to:
STR 10 (6.25) 2.5–10.0 3 (12.5) 0.73–25.73 13 (7.1) 3.39–10.81
INH 40 (25) 18.29–31.71 4 (20) 4.0–36.0 44 (23.9) 17.74–30.06
RIF 10 (6.25) 2.5–10.0 2 (8.3) 2.74–19.34 12 (6.5) 2.94–10.06
EMB 21 (13) 7.87–18.33 4 (16.7) 1.78–31.62 25 (13.6) 8.65–18.55
Mono Resistance to
STR 4 (2.5) 0.08–4. 92 0 (0) - 4 (2.2) 0.08–4.32
INH 25 (15.6) 9.98–21.22 0 (0) - 25 (13.6) 8.65–18.55
RIF 1 (0.63) 0.6–1.86 0 (0) - 1 (0.5) 0.52–1.52
EMB 10 (6.25) 2.5–10.0 1 (4.16) 3.83–12.15 11 (6.0) 2.57–9.43
INH + RIF Resistant (MDR)
INH + RIF only 4 (2.5) 0.08–4.92 0 (0) - 4 (2.2) 0.08–4.32
INH + RIF + EMB 1 (0.63) 0.6–1.86 0 (0) - 1 (0.5) 0.52–1.52
INH + RIF + STR 0 (0) 0 (0) - 0 (0) -
INH + RIF + EMB + STR 2 (1.25) 0.47–2.97 2 (8.3) 2.74–19.34 4 (2.2) 0.08–4.32
Total MDR 7 (4.4) 1.22–7.58 2 (8.3) 2.74–19.34 9 (4.9) 1.78–8.02
INH + other Resistance
INH + STR 3 (1.9) 0.22–4.02 1 (4.16) 3.83–12.15 4 (2.2) 0.08–4.32
INH + EMB 5 (3.1) 0.41–5.79 1 (4.16) 3.83–12.15 6 (3.3) 0.72–5.88
INH + STR + EMB 1 (0.63) 0.6–1.86 0 (0) - 1 (0.5) 0.52–1.52
RIF + other Resistance
RIF + EMB 1 (0.63) 0.6–1.86 0 (0) - 1 (0.5) 0.52–1.52
RIF + STR + EMB 1 (0.63) 0.6–1.86 0 (0) - 1 (0.5) 0.52–1.52
Table 3 Bivariate analysis of various risk factors for MDR
development
Category OR 95 % CI P value
Lower upper
Previous TB treatment 1.987 0.388 10.18 0.332
Previous TB infection 1.714 0.337 8.728 0.622
Contact with TB case 1.535 0.368 6.401 0.693
Resistance to any one drug 3.365 2.68 4.27 0.001
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survey shows a probability that new TB cases were in-
fected with a strain which is already drug resistant. There
are several factors that could lead to high MDR TB in
slums. Primary risk factors include poverty, malnutrition
and overcrowding. A study by Muture et al. [31] found
out that a majority of smear positive TB patients did not
stay long enough in treatment to convert to smear nega-
tive. With the presence of defaulters combined with
overcrowding and poor housing observed in the slums,
the frequency and intensity of interpersonal contact is
increased and this amplifies the risk of contagion droplet
or airborne infection. The possible association between
HIV infection in patients in slums and anti-TB drug resist-
ance could also be a factor aiding the spread of TB. Mal-
absorption of anti-TB drugs among HIV-positive patients,
poor treatment adherence and lack of access to proper
treatment could accelerate the spread of drug resistant TB
[31]. Emphases on measures to effectively control in-
fections within communities are necessary to improve on
the large burden of disease. Intensified case finding and
screening procedures will be beneficial to timely initiation
of appropriate therapy and reduction of further transmis-
sion of TB. Rapid and accurate diagnosis of drug res-
istance should be accompanied by accessibility to second
line drugs. Patients infected with drug resistant TB
require supportive mechanisms to be able to comply to
the lengthy treatment regimens.
One important limitation of this study is that HIV
status patient data were not available for analysis, hence
restricting our ability to derive concerete conclusions.
HIV infection is the strongest risk factor for TB patients.
In HIV infected individuals, TB is also the leading cause
of death since it accelerates the course of HIV infection
and increases viral load in some patients. HIV infection
may also contribute to the increase in MDR TB among
TB patients.
Conclusion
This study demonstrates that the overall resistance to
first line anti-TB drugs in Kenya is high. The highest
mono resistance was detected against INH, also pos-
ing a potential risk to generate more MDR cases by
ineffective treatment. The prevalence of MDR-TB is
relatively high, signifying conditions favouring the
spread of DR-TB are on the rise. Early case detection
and treatment, better patient compliance, expanding
diagnostic capacity for mycobacterial culture and drug
susceptibility testing are vital steps to limit further
spread of drug resistant TB strains in the slum set-
ting. Prompt and accurate detection of drug resist-
ance will be critical to timely initiation of treatment
hence prevent further transmission and allows selec-
tion of a drug regimen to which the infecting strain
is susceptible.
Additional file
Additional file 1: Tuberculosis Health Assessment questionnaire. Socio-
demographic data. Collects sociodemographic data such as age, sex,
marital status, education level, type of housing, sources of income,
number of people in a household and health behaviours. (DOC 33 kb)
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